Darunavir

Wissam I. El-Atrouni; Zelalem Temesgen

doi:10.1358/dot.2007.43.10.1131764

Darunavir

Wissam I. El-Atrouni, Zelalem Temesgen

Infectious Diseases

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.

Original language	English (US)
Pages (from-to)	671-679
Number of pages	9
Journal	Drugs of Today
Volume	43
Issue number	10
DOIs	https://doi.org/10.1358/dot.2007.43.10.1131764
State	Published - Oct 2007

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dot.2007.43.10.1131764

Cite this

@article{706f3d09498a4035bf6be166a0a1214a,

title = "Darunavir",

abstract = "Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.",

author = "El-Atrouni, {Wissam I.} and Zelalem Temesgen",

year = "2007",

month = oct,

doi = "10.1358/dot.2007.43.10.1131764",

language = "English (US)",

volume = "43",

pages = "671--679",

journal = "Drugs of Today",

issn = "1699-3993",

publisher = "Prous Science",

number = "10",

}

TY - JOUR

T1 - Darunavir

AU - El-Atrouni, Wissam I.

AU - Temesgen, Zelalem

PY - 2007/10

Y1 - 2007/10

N2 - Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.

AB - Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic responses superior to comparator-based regimens.

UR - http://www.scopus.com/inward/record.url?scp=36849050220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849050220&partnerID=8YFLogxK

U2 - 10.1358/dot.2007.43.10.1131764

DO - 10.1358/dot.2007.43.10.1131764

M3 - Review article

C2 - 17987220

AN - SCOPUS:36849050220

SN - 1699-3993

VL - 43

SP - 671

EP - 679

JO - Drugs of Today

JF - Drugs of Today

IS - 10

ER -

Darunavir

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this